Literature DB >> 2257211

Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer.

H Onodera1, S S Somers, P J Guillou.   

Abstract

The effects of treatment with 5-FU/folinic acid on interleukin-2 related lymphocyte responses was investigated in 21 patients with advanced colorectal cancer. The treatment was not suppressive of IL-2 related lymphocyte responses. Furthermore, at certain time points in the treatment cycles the capacity to generate lymphokine-activated killer (LAK) cells from the peripheral blood mononuclear cells of these patients was significantly augmented above that observed prior to treatment. These results provide a logical basis for the design of regimens which combine two approaches, each of low individual therapeutic efficacy, to treat patients with advanced colorectal cancer in the hope of increasing clinical response rates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2257211      PMCID: PMC1971584          DOI: 10.1038/bjc.1990.436

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  A T-cell receptor gamma/CD3 complex found on cloned functional lymphocytes.

Authors:  J Borst; R J van de Griend; J W van Oostveen; S L Ang; C J Melief; J G Seidman; R L Bolhuis
Journal:  Nature       Date:  1987 Feb 19-25       Impact factor: 49.962

2.  Reduced natural cytotoxic cell activity in patients receiving cisplatin-based chemotherapy and in mice treated with cisplatin.

Authors:  C B Powell; D G Mutch; M S Kao; J L Collins
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Effects of chemotherapeutic agents on the immune response. I.

Authors:  R A Kempf; M S Mitchell
Journal:  Cancer Invest       Date:  1984       Impact factor: 2.176

5.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

Authors:  M Rosenstein; S E Ettinghausen; S A Rosenberg
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

6.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

7.  Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

Authors:  J T Vetto; M Z Papa; M T Lotze; A E Chang; S A Rosenberg
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

8.  Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.

Authors:  M Z Papa; J T Vetto; S E Ettinghausen; J J Mulé; S A Rosenberg
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

9.  Decreased interleukin-2 production in patients with gastrointestinal cancer.

Authors:  J R Monson; C Ramsden; P J Guillou
Journal:  Br J Surg       Date:  1986-06       Impact factor: 6.939

10.  Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients.

Authors:  S Arinaga; T Akiyoshi; H Tsuji
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

View more
  3 in total

1.  Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.

Authors:  Z Gazit; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

Review 2.  Cytokine-based biotherapy of gastrointestinal tumors.

Authors:  J Buer; H Kirchner; A Schomburg; A Schüler; M Manns; E Lopez-Hänninen; S Duensing; H Poliwoda; J Atzpodien
Journal:  Clin Investig       Date:  1994-07

3.  Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.

Authors:  S H Goey; J W Gratama; J N Primrose; U Ward; R H Mertelsmann; B Osterwalder; J Verweij; G Stoter
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.